A systematic review of 87 studies has found that patients with multiple sclerosis have a slightly increased mortality risk from COVID-19, notably those who are older with significant disability and/or comorbidities (Barzegar et al. Neurol Neuroimmunol Neuroinflamm 2021;8:e1001). Read More
Latest News
Anti-CD20 therapies – Mechanisms of action
May 25, 2021Provides information on CD20, binding epitopes of anti-CD20 monoclonal antibodies (rituximab, ocrelizumab, ofatumumab, ublituximab) and the effects of anti-CD20 MAbs in multiple sclerosis. Includes slides explaining antibody-dependent cell-mediated cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC).
12 slides
Slide deck: COVID-19 – Epidemiology in Canada (May 17, 2021)
May 17, 2021Summary of epidemiology, testing and mortality rate; Canada and world statistics.
Variable vaccine efficacy against CoV-2 variants
May 11, 2021The mRNA vaccines used to prevent COVID-19 appear to be highly effective against variants of concern, in contrast to the reduced efficacy seen with other vaccine technologies. Read More